Who Owns BridgeBio Pharma Stock?
NASDAQ: BBIOHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 99.55%
- Institutions (% of float)
- 103.60%
- Held by insiders
- 3.91%
- Institutional holders
- 648
- Institutions 96.1%
- Insiders 3.9%
- Public and other 0.0%
Who owns BridgeBio Pharma stock?
Institutional investors own about 99.6% of BridgeBio Pharma's shares, spread across 648 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.91% of BBIO.
The largest institutional holders are Jupiter Topco LLC (7.22%), Kohlberg Kravis Roberts & Co. L.P. (6.78%) and Farallon Capital Management LLC (5.50%). Together, the top 10 institutions control 45.3% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their BBIO positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BBIO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Jupiter Topco LLC | 14.11M | 7.22% | +100.0% |
| Kohlberg Kravis Roberts & Co. L.P. | 13.26M | 6.78% | 0.0% |
| Farallon Capital Management LLC | 10.74M | 5.50% | +14.7% |
| Blackrock Inc. | 10.29M | 5.26% | -27.6% |
| Viking Global Investors, L.P. | 9.95M | 5.09% | -16.0% |
| Vanguard Capital Management LLC | 7.90M | 4.04% | +1.8% |
| Vanguard Portfolio Management LLC | 7.66M | 3.92% | -5.3% |
| Wellington Management Group, LLP | 5.31M | 2.72% | +113.7% |
| Two Sigma Investments, LP | 4.72M | 2.42% | +51.3% |
| Aisling Capital Management LP | 4.59M | 2.35% | -9.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BBIO
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5.60M | 2.86% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 4.04M | 2.07% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.16M | 1.62% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 2.33M | 1.19% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.97M | 1.01% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 1.91M | 0.98% |
| Vanguard Explorer Fund | 1.72M | 0.88% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.59M | 0.81% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.56M | 0.80% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.32M | 0.67% |
Frequently asked questions
Who is the largest shareholder of BridgeBio Pharma?
Jupiter Topco LLC is the largest institutional shareholder of BBIO, owning 7.22% of shares outstanding (14.11M shares) as of its latest 13F filing.
What percentage of BridgeBio Pharma is owned by institutions?
Institutions own about 99.6% of BBIO shares and 103.6% of the public float.
How much of BridgeBio Pharma do insiders own?
Insiders, such as officers and directors, own about 3.91% of BBIO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.